Endogenous Nitroalkene Exploits Dependence on Autophagy-Lysosome Pathway in PARPi-Resistant TNBC
Lisa HongiD, Sanghoon LeeiD, Leonard G. FrisbieiD, Yaoning ZhaoiD, John SkokoiD, Christopher MerkeliD, Tetsushi KatauraiD, Viktor I. KorolchukiD, Lan Gardner CoffmaniD, Adrian V. LeeiD, Bruce Α. FreemaniD, Francisco Jose SchopferiD, Carola Anke NeumanniD
Abstract
Lack of DNA double-strand break repair efficiency exquisitely sensitizes cancers to poly-ADP ribose polymerase inhibitors (PARPi). Unfortunately, resistance to PARPi poses an insurmountable challenge for patients. Mechanisms that confer insensitivity to PARPi therapy include enhanced DNA damage repair and autophagy. Natural and non-natural unsaturated fatty acid nitroalkene derivatives (NFA) show anticancer actions that sensitize TNBC cells to PARPi and other DNA-damaging treatments. We reveal that nitro-oleic acid (OA-NO2) re-sensitizes PARPi-resistant TNBC cells to PARPi. RNA-seq analysis of clinically relevant mutBRCA1 PARPi-resistant TNBC cell lines exhibited upregulation in autophagy and lysosomal pathways. Bio-orthogonal analysis identified the autophagy regulator SQSTM1/p62 as a novel OA-NO2 target, alkylating two redox-sensitive Cys residues of p62 (Cys105 and Cys113). These Cys are essential for p62 regulation of autophagy and mimicked the effects of p62 Cys105 and Cys113Ala mutants and when alkylated by OA-NO2 showed impaired p62 oligomerization, degradation, and inhibition of autophagy. Combination treatment of PARPi-resistant TNBC with a PARPi and OA-NO2 synergistically inhibited p62-associated autophagy and lysosome function. These data emphasize the clinical potential of OA-NO2 for treating PARPi-resistant TNBC patients.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting ribosome biogenesis sensitizes PARPi-resistant triple-negative breast cancer
Mallory I. Frederick, Nicolas Pouderous, … Saima Noor Hassan·bioRxiv·Oct 9, 2026
- Nuclear NAD+ homeostasis is essential for naive and chemoresistant BRCA1/2-deficient tumor survival
D. Musiani, H. Yucel, … R. Ceccaldi·bioRxiv·Dec 9, 2021
- Nucleophagy removes cytotoxic trapped PARP1
Gwendoline Hoslett, Sara Tribble, … Kristijan Ramadan·Nature Cell BiologyPeer-reviewed·Jun 1, 2026
- Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors
J. Zhou, C. Gelot, … A. D. D'Andrea·bioRxiv·May 23, 2020
- Targeting FEN1 to enhance efficacy of PARP inhibition in triple-negative breast cancer
Mallory I. Frederick, Elicia Fyle, … Saima Noor Hassan·Translational OncologyPeer-reviewed·Mar 6, 2025
- Small molecule nitroalkenes inhibit RAD51-mediated homologous recombination and amplify triple-negative breast cancer cell killing by DNA-directed therapies.
L. Hong, d. C. Braden, … C. A. Carola·bioRxiv·Aug 11, 2023